UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
x | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended July 31, 2007
¨ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from to
Commission file number 0-5286
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 38-0715562 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
2700 West Front Street Statesville, North Carolina |
28677 | |
(Address of principal executive offices) | (Zip Code) |
(704) 873-7202
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x
As of September 5, 2007, the Registrant had outstanding 2,519,820 shares of Common Stock.
Pages: This report, excluding exhibits, contains 18 pages numbered sequentially from this cover page.
KEWAUNEE SCIENTIFIC CORPORATION
FOR THE QUARTERLY PERIOD ENDED JULY 31, 2007
2
Kewaunee Scientific Corporation
Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
Three months ended July 31 |
||||||||
2007 | 2006 | |||||||
Net sales |
$ | 20,784 | $ | 19,294 | ||||
Costs of products sold |
16,521 | 16,166 | ||||||
Gross profit |
4,263 | 3,128 | ||||||
Operating expenses |
3,148 | 2,637 | ||||||
Operating earnings |
1,115 | 491 | ||||||
Other income |
3 | 18 | ||||||
Interest expense |
(110 | ) | (187 | ) | ||||
Earnings before income taxes |
1,008 | 322 | ||||||
Income tax expense |
312 | 78 | ||||||
Earnings before minority interests |
696 | 244 | ||||||
Minority interests in subsidiaries |
22 | 111 | ||||||
Net earnings |
$ | 674 | $ | 133 | ||||
Net earnings per share |
||||||||
Basic |
$ | 0.27 | $ | 0.05 | ||||
Diluted |
$ | 0.27 | $ | 0.05 | ||||
Weighted average number of common shares outstanding (in thousands) |
||||||||
Basic |
2,502 | 2,492 | ||||||
Diluted |
2,521 | 2,493 |
See accompanying notes to consolidated financial statements.
3
Kewaunee Scientific Corporation
Consolidated Balance Sheets
(in thousands)
July 31 2007 |
April 30 2007 |
|||||||
(Unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,791 | $ | 2,231 | ||||
Restricted cash |
396 | 372 | ||||||
Receivables, less allowance |
18,868 | 19,061 | ||||||
Inventories |
5,694 | 5,869 | ||||||
Deferred income taxes |
297 | 297 | ||||||
Prepaid expenses and other current assets |
1,071 | 684 | ||||||
Total current assets |
28,117 | 28,514 | ||||||
Property, plant and equipment, at cost |
37,342 | 37,096 | ||||||
Accumulated depreciation |
(26,146 | ) | (25,841 | ) | ||||
Net property, plant and equipment |
11,196 | 11,255 | ||||||
Prepaid pension cost |
2,025 | 1,911 | ||||||
Deferred income taxes |
129 | 129 | ||||||
Other |
3,432 | 3,431 | ||||||
Total other assets |
5,586 | 5,471 | ||||||
Total Assets |
$ | 44,899 | $ | 45,240 | ||||
Liabilities and Stockholders Equity |
||||||||
Current liabilities: |
||||||||
Short-term borrowings |
$ | 4,556 | $ | 3,489 | ||||
Current obligations under capital leases |
369 | 360 | ||||||
Accounts payable |
7,107 | 8,437 | ||||||
Employee compensation and amounts withheld |
1,088 | 1,416 | ||||||
Deferred revenue |
712 | 1,672 | ||||||
Other accrued expenses |
1,334 | 809 | ||||||
Total current liabilities |
15,166 | 16,183 | ||||||
Obligations under capital leases |
381 | 476 | ||||||
Accrued employee benefit plan costs |
3,351 | 3,351 | ||||||
Minority interests in subsidiaries |
1,211 | 1,182 | ||||||
Total Liabilities |
20,109 | 21,192 | ||||||
Stockholders equity: |
||||||||
Common stock |
6,550 | 6,550 | ||||||
Additional paid-in-capital |
211 | 155 | ||||||
Retained earnings |
20,446 | 19,947 | ||||||
Accumulated other comprehensive loss |
(1,780 | ) | (1,833 | ) | ||||
Common stock in treasury, at cost |
(637 | ) | (771 | ) | ||||
Total stockholders equity |
24,790 | 24,048 | ||||||
Total Liabilities and Stockholders Equity |
$ | 44,899 | $ | 45,240 | ||||
See accompanying notes to consolidated financial statements.
4
Kewaunee Scientific Corporation
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands )
Three months ended July 31 |
||||||||
2007 | 2006 | |||||||
Cash flows from operating activities: |
||||||||
Net earnings |
$ | 674 | $ | 133 | ||||
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: |
||||||||
Depreciation |
494 | 486 | ||||||
Provision for bad debts |
88 | 2 | ||||||
Decrease in prepaid income taxes |
| 11 | ||||||
Decrease in receivables |
105 | 4,083 | ||||||
Decrease (increase) in inventories |
175 | (296 | ) | |||||
Increase in prepaid pension cost |
(114 | ) | (101 | ) | ||||
Decrease in accounts payable and other current liabilities |
(1,133 | ) | (2,744 | ) | ||||
(Decrease) increase in deferred revenue |
(960 | ) | 52 | |||||
Other, net |
(306 | ) | (220 | ) | ||||
Net cash (used in) provided by operating activities |
(977 | ) | 1,406 | |||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
(435 | ) | (322 | ) | ||||
Increase in restricted cash |
(24 | ) | (1 | ) | ||||
Net cash used in investing activities |
(459 | ) | (323 | ) | ||||
Cash flows from financing activities: |
||||||||
Dividends paid |
(175 | ) | (175 | ) | ||||
Increase in short-term borrowings |
1,067 | 315 | ||||||
Payments on capital leases |
(86 | ) | (65 | ) | ||||
Proceeds from exercise of stock options (including tax benefit) |
190 | | ||||||
Net cash provided by financing activities |
996 | 75 | ||||||
(Decrease) increase in cash and cash equivalents |
(440 | ) | 1,158 | |||||
Cash and cash equivalents, beginning of period |
2,231 | 929 | ||||||
Cash and cash equivalents, end of period |
$ | 1,791 | $ | 2,087 | ||||
See accompanying notes to consolidated financial statements.
5
Kewaunee Scientific Corporation
Notes to Consolidated Financial Statements
(unaudited)
A. Financial Information
The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim consolidated financial statements should be read in conjunction with the financial statements and notes included in the Companys 2007 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
The preparation of the consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
B. Inventories
Inventories consisted of the following (in thousands):
July 31, 2007 | April 30, 2007 | |||||
Finished products |
$ | 1,287 | $ | 1,243 | ||
Work in process |
1,388 | 1,257 | ||||
Raw materials |
3,019 | 3,369 | ||||
$ | 5,694 | $ | 5,869 | |||
For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur.
6
C. Comprehensive Income
A reconciliation of net earnings and total comprehensive income for the three months ended July 31, 2007 and 2006 is as follows (in thousands):
Three months ended July 31, 2007 |
Three months ended July 31, 2006 |
||||||
Net earnings |
$ | 674 | $ | 133 | |||
Change in cumulative foreign currency translation adjustments |
53 | (34 | ) | ||||
Total comprehensive income |
$ | 727 | $ | 99 |
Assets and liabilities for the Companys foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders equity.
D. Share-Based Compensation
Effective May 1, 2006, the Company adopted the fair-value recognition provisions of SFAS No. 123(R), Share-Based Payment, using the modified prospective transition method. Under this transition method, the Company recorded stock-based compensation expense for the three months ended July 31, 2006 of $574. There was no expense under this transition method for the three months ended July 31, 2007.
E. Segment Information
The following table provides financial information by business segments for the three months ended July 31, 2007 and 2006 (in thousands):
Domestic Operations |
International Operations |
Corporate | Total | |||||||||||
Three months ended July 31, 2007 |
||||||||||||||
Revenues from external customers |
$ | 18,014 | $ | 2,770 | $ | | $ | 20,784 | ||||||
Intersegment revenues |
776 | 89 | (865 | ) | | |||||||||
Operating earnings (loss) before income taxes |
1,672 | (2 | ) | (662 | ) | 1,008 | ||||||||
Three months ended July 31, 2006 |
||||||||||||||
Revenues from external customers |
$ | 16,674 | $ | 2,620 | $ | | $ | 19,294 | ||||||
Intersegment revenues |
882 | 142 | (1,024 | ) | | |||||||||
Operating earnings (loss) before income taxes |
547 | 348 | (573 | ) | 322 |
7
F. Defined Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. Effective April 30, 2005, no further benefits have been, or will be, earned under the plans, and no additional participants will be added to the plans. No contributions were paid to the plans during the three months ended July 31, 2007, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year.
Pension expense (income) consisted of the following (in thousands):
Three months ended July 31, 2007 |
Three months ended July 31, 2006 |
|||||||
Service Cost |
$ | -0- | $ | -0- | ||||
Interest Cost |
215 | 208 | ||||||
Expected return on plan assets |
(365 | ) | (347 | ) | ||||
Amortization of prior service costs |
-0- | -0- | ||||||
Recognition of net loss |
35 | 38 | ||||||
Net periodic pension cost (income) |
$ | (115 | ) | $ | (101 | ) |
G. Recent Accounting Pronouncements
In June 2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48 or the Interpretation) which defines the threshold for recognizing the benefits of tax return positions in the financial statements as more-likely-than-not to be sustained by the taxing authority. The Company adopted the Interpretation during the quarter ended July 31, 2007 with no impact on its consolidated financial position or results of operations.
8
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
The Companys 2007 Annual Report to Stockholders contains managements discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2007. The following discussion and analysis describes material changes in the Companys financial condition since April 30, 2007. The analysis of results of operations compares the three months ended July 31, 2007 with the comparable period of the prior fiscal year.
Results of Operations
Sales for the three months ended July 31, 2007 were $20,784,000, an increase of 7.7% from sales of $19,294,000 in the same period last year. Sales from Domestic Operations were $18,014,000, an increase of 8% from the prior year period. Sales from International Operations were $2,770,000, an increase of 5.7% from the prior year period. The order backlog at July 31, 2007 was $54.7 million, as compared to a backlog of $51.1 million at April 30, 2007 and $36.5 million at July 31, 2006.
The gross profit margin for the three months ended July 31, 2007 was 20.5% of sales, as compared to 16.2% of sales in the comparable quarter of the prior year. The increase in gross profit margin was due to increased manufacturing efficiencies, savings from alternative sources of raw materials and components, and other cost improvement initiatives.
Operating expenses for the three months ended July 31, 2007 were $3.1 million, or 15.1% of sales, as compared to $2.6 million, or 13.7% of sales, in the comparable period of the prior year. The increase in operating expenses was primarily due to an increase in sales and marketing expenses of $97,000, an increase in bad debt expense of $86,000, and increases in consulting and legal expenses of $81,000.
Operating earnings were $1,115,000 for the three months ended July 31, 2007. This compares to operating earnings of $491,000 for the comparable period of the prior year.
Interest expense was $109,697 for the three months ended July 31, 2007, as compared to $187,000 for the same period of the prior year. The decrease in interest expense for the current year period resulted from lower borrowing levels as compared to the prior year period.
Other income was $3,000 in the three months ended July 31, 2007, as compared to other expense of $18,000 for the comparable period of the prior year.
9
Income tax expense of $312,000 was recorded for the three months ended July 31, 2007, as compared to income tax expense of $78,000 recorded for the comparable period of the prior year. The effective tax rate was 30.9% for the three months ended July 31, 2007 and was 24.1% for the three months ended July 31, 2006. The effective tax rate for the three months ended July 31, 2007 differs from the statutory rate primarily due to the impact of earned state and federal tax credits, and to a lesser degree, due to the varying income tax rates on income earned by the Companys foreign subsidiaries. In addition to these factors, the effective tax rate in the prior year period was impacted by the lower level of operating earnings for that period.
Minority interests result from the Companys two subsidiaries that are not 100% owned by the Company. Minority interests reduced net earnings by $22,000 for the three months ended July 31, 2007, as compared to a reduction of $111,000 for the comparable period of the prior year. The decrease in minority interests in the current period was directly related to decreased earnings of the two subsidiaries.
Net earnings were $674,000, or $0.27 per diluted share, for the three months ended July 31, 2007. This compares to net earnings of $133,000, or $.05 per diluted share, for the comparable period of the prior year.
Liquidity and Capital Resources
Historically, the Companys principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Companys revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.
The Company had working capital of $13.0 million at July 31, 2007, compared to $12.3 million at April 30, 2007. The ratio of current assets to current liabilities was 1.9-to-1 at July 31, 2007, as compared to 1.8-to-1 at April 30, 2007. At July 31, 2007, advances of $4,556,000 were outstanding under the unsecured credit facility.
The Companys operations used cash of $977,000 during the three months ended July 31, 2007. Cash was primarily used to fund a decrease in accounts payable and other current liabilities, and a decrease in deferred revenue. The impact of these items was partially offset by cash provided from operating earnings.
10
The Companys operations provided cash of $1,406,000 during the three months ended July 31, 2006. Cash was provided primarily from a decrease in accounts receivable which was partially offset by cash used to decrease accounts payable and other current liabilities.
During the three months ended July 31, 2007, net cash of $459,000 was used by investing activities, primarily for capital expenditures. This compares to the use of $323,000 for investing activities in the same period of the prior year, primarily for capital expenditures.
The Companys financing activities provided cash of $996,000 during the three months ended July 31, 2007. Cash provided included $1,067,000 received from short-term borrowings and $190,000 from proceeds from stock options exercised, which was offset by cash dividends paid of $175,000 and payments on obligations of capital leases of $86,000. Financing activities provided cash of $75,000 in the same period of the prior year, which included $315,000 received from short-term borrowings, offset by $175,000 for cash dividends, and payment on obligations of capital leases of $65,000.
Outlook for Remainder of Fiscal Year 2008
While the Companys ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Companys role as subcontractor or supplier to dealers for subcontractors, the Company expects the remainder of fiscal year 2008 to be profitable. In addition to general economic factors affecting the Company and its markets, demand for its products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Companys earnings are also impacted by increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales.
11
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Companys operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes, belief, expects, plans, objectives, anticipates, intends or the like to be uncertain and forward-looking. Over time, the Companys actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Companys forward-looking statements, and such difference might be significant and harmful to stockholders interest. Many important factors that could cause such a difference are described under the caption Risk Factors, in Item 1A of the Companys 2007 Annual Report on Form 10-K.
12
REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three month periods ended July 31, 2007 and July 31, 2006 has been performed by Cherry, Bekaert & Holland, L.L.P., the Companys independent auditors. Their report on the interim financial information follows.
13
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have reviewed the accompanying consolidated balance sheets of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of July 31, 2007, and the related consolidated statements of operations and of cash flows for the three-month periods ended July 31, 2007 and 2006. These interim consolidated financial statements are the responsibility of the Companys management.
We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.
We previously audited, in accordance with the Standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2007, and the related statements of operations, of stockholders equity and of cash flows for the year then ended (not presented herein) and in our report dated July 12, 2007, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2007 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.
Cherry, Bekaert & Holland, L.L.P.
Charlotte, North Carolina
September 4, 2007
14
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
There are no material changes to the disclosures made on this matter in the Companys Annual Report on Form 10-K for the fiscal year ended April 30, 2007.
Item 4. | Controls and Procedures |
(a) Evaluation of disclosure controls and procedures
An evaluation was performed under the supervision and the participation of the Companys management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2007. Based on that evaluation, the Companys management, including the CEO and CFO, concluded that, as of July 31, 2007, the Companys disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) Changes in internal controls
There was no change in the Companys internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.
15
Item 4. | Submission of Matters to a Vote of Security Holders |
The Companys Annual Meeting of Stockholders was held on August 22, 2007. Each of the nominees for Class III directors was re-elected for a three-year term. The votes cast for and withheld from each such director were as follows:
Director |
For | Withheld | ||
Margaret B. Pyle |
2,357,167 | 1,079 | ||
Eli Manchester, Jr. |
2,111,096 | 247,150 |
Item 5. | Other Information |
On August 22, 2007, the Companys Board of Directors adopted the Fiscal Year 2008 Incentive Bonus Plan (the Plan). All of the Companys executive officers will be eligible to participate in the Plan. Eligible participants will be nominated by the President and approved by the Board of Directors, upon the recommendation of the Compensation Committee. A participant will share in a bonus pool up to a specified percentage of his or her base salary. The bonus pool will begin accumulating once specified thresholds of operating income (with respect to specific operating units) and pre-tax earnings (with respect to corporate performance) are achieved. If the threshold levels are not achieved, no bonus will be paid, except at the discretion of the Board of Directors upon the recommendation of the Compensation Committee. A fixed bonus equal to 75% of a participants bonus potential will be based on achievement of earnings goals, and a discretionary bonus of up to 25% of a participants bonus may be awarded by the Board of Directors upon recommendation of the President and the Compensation Committee, taking into account the participants achievement of his or her personal goals. A copy of the Plan is filed as Exhibit 10.47 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.
Item 6. | Exhibits |
10.47 | Fiscal Year 2008 Incentive Bonus Plan | |
31.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
16
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION | ||||||||
(Registrant) | ||||||||
Date: September 10, 2007 | By | /s/ D. Michael Parker | ||||||
D. Michael Parker | ||||||||
Senior Vice President, Finance and | ||||||||
Chief Financial Officer |
17